Donald Lawrence Wickerham
#164,249
Most Influential Person Now
Donald Lawrence Wickerham's AcademicInfluence.com Rankings
Donald Lawrence Wickerhamphilosophy Degrees
Philosophy
#9594
World Rank
#13178
Historical Rank
Logic
#6563
World Rank
#8091
Historical Rank
Donald Lawrence Wickerhambiology Degrees
Biology
#13209
World Rank
#16742
Historical Rank
Molecular Biology
#2207
World Rank
#2241
Historical Rank
Download Badge
Philosophy Biology
Donald Lawrence Wickerham's Degrees
- PhD Molecular Biology University of California, Berkeley
- Doctorate Medicine Stanford University
Why Is Donald Lawrence Wickerham Influential?
(Suggest an Edit or Addition)Donald Lawrence Wickerham's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (2004) (5593)
- Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (5389)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) (2385)
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. (1998) (2102)
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (1997) (1718)
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. (1989) (1427)
- Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. (1985) (1318)
- Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2005) (1251)
- Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. (1995) (1131)
- The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2003) (1080)
- Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update (1983) (1010)
- Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. (1988) (1003)
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) (985)
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2006) (907)
- Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. (1996) (884)
- Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. (1993) (821)
- Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. (2005) (695)
- erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. (1998) (674)
- Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. (1994) (662)
- The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. (1993) (656)
- Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. (1998) (637)
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe (1990) (593)
- Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. (2002) (574)
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. (2010) (543)
- Significance of ipsilateral breast tumour recurrence after lumpectomy (1991) (517)
- Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. (1997) (512)
- Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. (2000) (506)
- Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. (2002) (492)
- Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2005) (488)
- Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. (1999) (469)
- Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. (2012) (457)
- Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (444)
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. (2009) (400)
- Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. (1988) (399)
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (2013) (398)
- A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum (1997) (384)
- A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. (1989) (379)
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. (1997) (325)
- HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. (2000) (322)
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. (2008) (310)
- Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. (1990) (302)
- Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. (1983) (274)
- Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. (2001) (260)
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (247)
- Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. (1999) (226)
- Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and (1996) (226)
- Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. (1985) (205)
- Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. (1990) (204)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Association of tamoxifen and uterine sarcoma. (2002) (196)
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 (2011) (191)
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. (1989) (151)
- Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. (2001) (144)
- Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. (2001) (134)
- Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. (1999) (133)
- Ductal carcinoma-in-situ. (2001) (121)
- Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. (1987) (117)
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer (2009) (114)
- Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
- Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group. (1997) (108)
- Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings. (1992) (108)
- Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer (2006) (107)
- Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy (2017) (103)
- Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials (2012) (103)
- Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
- Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. (2004) (99)
- Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials (2010) (90)
- Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. (2005) (89)
- The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. (2002) (88)
- Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. (2003) (82)
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
- Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (2007) (75)
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (74)
- Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. (2007) (74)
- Lower-category benign breast disease and the risk of invasive breast cancer. (2004) (71)
- Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). (2006) (69)
- Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial (2003) (67)
- Prevention of hormone-related cancers: breast cancer. (2005) (66)
- Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial (2011) (65)
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
- Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups (2011) (58)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (58)
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
- Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. (2006) (55)
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
- National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. (2003) (46)
- Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. (1989) (45)
- Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group (2009) (44)
- Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene (2012) (43)
- Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. (1983) (42)
- Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer (2004) (42)
- Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies (2012) (41)
- Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer. (1992) (36)
- Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial (2014) (36)
- The use of tamoxifen and raloxifene for the prevention of breast cancer. (2009) (32)
- Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene (2005) (32)
- Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01 (2017) (30)
- Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. (2012) (30)
- Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. (2016) (29)
- Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. (2013) (27)
- Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). (2011) (27)
- Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight‐year results from the national surgical adjuvant breast and bowel project B‐10 (1990) (27)
- Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2012) (25)
- Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion (2017) (23)
- Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 (2012) (23)
- Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. (2004) (22)
- Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials (2011) (22)
- A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 (2015) (21)
- The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. (2006) (20)
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities (2013) (20)
- Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy (2005) (19)
- Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer (2015) (18)
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. (2010) (17)
- NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction (2017) (16)
- Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01. (2010) (16)
- Helping breast cancer patients adhere to oral adjuvant hormonal therapy regimens (2007) (15)
- The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with met (1994) (15)
- UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer. (1999) (15)
- The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project (2006) (15)
- Breast cancer chemoprevention: current status and future directions. (2001) (15)
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. (2008) (14)
- Ductal carcinoma in situ: a rose by any other name. (2013) (13)
- Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer (2015) (12)
- Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial. (2003) (12)
- Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes (2017) (12)
- Identification of accrual barriers onto breast cancer prevention clinical trials (2010) (12)
- Tamoxifen versus raloxifene in the prevention of breast cancer. (2002) (11)
- Breast cancer chemoprevention: the saga of underuse continues. (2014) (11)
- IS TAMOXIFEN A RISK FACTOR FOR RETINAL VASO-OCCLUSIVE DISEASE? (2005) (10)
- Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. (2009) (10)
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
- Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). (2017) (8)
- NSABP Protocol B-06: A randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer — Results after 15 years of follow-up (1998) (8)
- The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. (2006) (7)
- Surgical treatment of primary breast cancer. (1988) (7)
- Future directions in the adjuvant treatment of colon cancer. (1997) (7)
- The Globalization of Cooperative Groups. (2015) (6)
- Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
- Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). (2011) (6)
- Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (2002) (5)
- Breast cancer chemoprevention: progress and controversy. (2010) (5)
- Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04. (2012) (4)
- Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01 (2008) (4)
- Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2008) (4)
- Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 (2012) (4)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- An update on breast cancer prevention trials. (2006) (3)
- Tamoxifen a nd C hemotherapy f or A xillary N ode-Negative, Estrogen R eceptor-Negativ e B reast C ancer: F indings F rom National S urgical A djuvant B reast a nd B owel P roject B -23 (2001) (3)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (3)
- Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
- Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (3)
- Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) (3)
- Abstract P6-10-01: Results from NRG oncology/NSABP protocol DMP-1: Women's decision-making in breast cancer risk reduction (2016) (2)
- Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. (2015) (2)
- Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. (2012) (2)
- Impact of ethnic neutropenia disparity analysis in NSABP breast trials of postoperative doxorubicin (A)/cyclophosphamide (C) (2005) (1)
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer (2023) (1)
- Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy (2015) (1)
- Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT). (2010) (1)
- The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment (2007) (1)
- Leukemia in Breast Cancer Patients Following Adjuvant Chemotherapy or Postoperative Radiation (2016) (1)
- The Use of Tramoxifen and Roloxifene for the Prevention of Breast Cancer (2009) (0)
- An aromatase inhibitor for breast cancer prevention: a promising option with barriers to resolve (2011) (0)
- Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less (2002) (0)
- Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
- Incidence Rates of Invasive Breast Cancer in Postmenopausal Women with and without a Family History of Breast Cancer and Stratified by Breast Cancer Risk Score. (2009) (0)
- S20. Tamoxifen or Raloxifen for chemoprevention of breast cancer in high risk women: The NSABP-experience (2008) (0)
- Demographic characteristics and quality of life factors among the participants of the breast cancer prevention trial (1998) (0)
- Abstracts reprinted from journal of clinical oncology (2007) (0)
- 57 Risk communication strategies during an ongoing clinical trial: Protecting participant safety without causing unnecessary panic, the breast cancer prevention trial (BCPT) experience (1997) (0)
- Routine preventive care and cancer surveillance in long-term survivors (LTS) of colorectal cancer: Results from NSABP Protocol LTS-01. (2009) (0)
- Answers to questions about breast cancer. (1986) (0)
- Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion (2017) (0)
- ductal Carcinoma in Situ: a r ose by any o ther Name (2013) (0)
- SP 124 Debate on strategies for data release: controlled access (2011) (0)
- 17 A review and assessment of the participant recruitment strategies employed in the NSABP Breast Cancer Prevention Trial (1997) (0)
- Abstract P6-10-03: The contribution of common genetic variation to breast cancer risk among women receiving tamoxifen or raloxifene within the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 trials (2015) (0)
- Title Cancer survivorship research : the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group Permalink (2009) (0)
- Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01. (2010) (0)
- Abstract 4727: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression (2011) (0)
- Session 5 S13. Impact of tamoxifen as a preventive agent in clinical practice and update of the STAR trial (2002) (0)
- Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial. (2014) (0)
- Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
- Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
- Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes (2017) (0)
- Results from NRG oncology/NSABP protocol DMP-1: Physician counseling. (2018) (0)
- Prolonging Tamoxifen Therapy for Primary Breast Cancer (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Donald Lawrence Wickerham?
Donald Lawrence Wickerham is affiliated with the following schools:
